Overview
What does it take to fuel the next wave of innovation in life sciences? The answer lies in investing strategically, collaborative learning and shared aspirations towards revolutionising healthcare. Join us on 28 February for our next event in the “Meet with Venture Capital” series – Meet with Brandon Capital! In this session, look forward to hearing from guest speaker Jonathan Tobin, Partner at Brandon Capital, and Alessandro Falcone, Head of JLABS Singapore, as they discuss the intersection of venture capital and the advancement of life sciences innovation.
Through strategic collaboration and investment, Brandon Capital has supported over 50 life science start-ups, including high profile ones such as the recent USD112M Series C financing of AdvanCell, USD150M Series D financing of CatalYm and USD114M Series A financing of Myricx Bio. Embrace this opportunity to gain fresh perspectives from the lenses of a life science venture capitalist, and don’t miss out on networking with investors and like-minded innovators!
As capacity is limited, please register to the waitlist and you will receive an email if your spot is confirmed. Thank you for your patience and understanding.
Photography and videography will be captured during this event. Through your participation, you are granting Johnson & Johnson Innovation - JLABS consent to utilize these images and videos for promotional purposes, which may include social media, website and publication purposes. If you do not wish to be photographed, kindly inform the photographer at the event.
Schedule
Date: 28 Feb 2025, Friday
Time: 3:30 PM - 6:30 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: HUONE, 3D River Valley Road, #03-01 Clarke Quay, Singapore 179023
Speakers
Speaker's Profile:
Jonathan Tobin, Partner, Brandon Capital
Jonathan is a Partner at Brandon’s London office and serves on the boards of Pheon, Myricx Pharma, NRG Therapeutics, AstronautX, Salvina, and Catalym. Previously, he was a Managing Director at Arix Bioscience, where he built the team and portfolio, sitting on boards including Artios Pharma and VelosBio (acquired by Merck for $2.75bn). Before Arix, Jonathan was a Principal at Touchstone Innovations, helping build biotech spin-outs like Inivata (acquired for $415m). He also worked at LifeArc in drug discovery. Jonathan holds a first-class Biology degree from Oxford, a PhD in Molecular Medicine from UCL, and an MBA from Imperial College London. He conducted postdoctoral research on cancer cell signaling at Cancer Research UK, publishing in Nature Genetics and NEJM. He is a trustee of the Autism Centre for Excellence and advises KHAN drug discovery fund.
Moderator's Profile:
Alessandro Falcone, Head, JLABS Singapore, Johnson & Johnson
Alessandro is responsible for charting the strategic direction and overseeing all portfolio and business operational activities. Before assuming this role, Alessandro held the position of Executive Director in Oncology R&D at AstraZeneca, concentrating on the clinical development of the breast cancer portfolio. Prior, he also occupied senior R&D and commercial positions at GSK and Novartis, respectively, over the past decade. At Novartis, he spearheaded European strategy and operations, while at GSK, he led technology and partnerships for all R&D endeavors. Alessandro's career encompasses significant experience at top life science strategy consultancies such as LEK and IQVIA, with a particular focus on international investments in the life science sector. He holds an MD from UCL, a first-class honours B.Sc. in Business & Healthcare Management from Imperial College London, and an M.Sc. with distinction in Experimental & Translational Therapeutics from the University of Oxford.
